Omeros Total Assets 2009-2019 | OMER

Omeros total assets from 2009 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
Omeros Annual Total Assets
(Millions of US $)
2018 $96
2017 $116
2016 $67
2015 $49
2014 $11
2013 $17
2012 $27
2011 $27
2010 $46
2009 $62
2008 $22
2007 $0
Omeros Quarterly Total Assets
(Millions of US $)
Q3 2019 $91
Q2 2019 $90
Q1 2019 $101
Q4 2018 $96
Q3 2018 $76
Q2 2018 $106
Q1 2018 $89
Q4 2017 $116
Q3 2017 $126
Q2 2017 $60
Q1 2017 $58
Q4 2016 $67
Q3 2016 $73
Q2 2016 $46
Q1 2016 $36
Q4 2015 $49
Q3 2015 $41
Q2 2015 $59
Q1 2015 $75
Q4 2014 $11
Q3 2014 $25
Q2 2014 $41
Q1 2014 $56
Q4 2013 $17
Q3 2013 $12
Q2 2013 $23
Q1 2013 $18
Q4 2012 $27
Q3 2012 $33
Q2 2012 $10
Q1 2012 $21
Q4 2011 $27
Q3 2011 $35
Q2 2011 $41
Q1 2011 $48
Q4 2010 $46
Q3 2010 $37
Q2 2010 $45
Q1 2010 $53
Q4 2009 $62
Q3 2009 $7
Q2 2009 $0
Q1 2009 $0
Q4 2008 $0
Q3 2008 $0
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.715B $0.030B
Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $149.187B 27.21
Medtronic (MDT) Ireland $148.912B 20.55
Stryker (SYK) United States $75.969B 25.54
Boston Scientific (BSX) United States $59.391B 28.03
Baxter (BAX) United States $41.360B 25.08
Essilor Luxottica (ESLOY) France $32.912B 0.00
Zimmer Biomet Holdings (ZBH) United States $29.495B 18.50
Terumo (TRUMY) Japan $27.172B 33.91
Coloplast (CLPBY) Denmark $25.315B 39.07
Lonza Group Ag (LZAGY) Switzerland $25.204B 0.00
ResMed (RMD) United States $21.492B 39.65
Smith & Nephew SNATS (SNN) United Kingdom $19.178B 0.00
Sunny Optical Technology (SNPTF) China $17.572B 0.00
Insulet (PODD) United States $11.378B 541.29
Bio-Rad Laboratories (BIO) United States $11.123B 53.39
William Demant Holdings (WILYY) Denmark $7.531B 0.00
Hill-Rom Holdings (HRC) United States $7.077B 20.87
Perrigo (PRGO) Ireland $6.765B 12.61
Canopy Growth (CGC) Canada $6.616B 0.00
DiaSorin S.p.A (DSRLF) Italy $6.420B 0.00
Haemonetics (HAE) United States $5.992B 40.49
Shandong Weigao Medical Polymer (SHWGF) China $5.743B 0.00
GN STORE NORD (GNNDY) Denmark $5.276B 27.26
ICU Medical (ICUI) United States $3.819B 24.90
NuVasive (NUVA) United States $3.787B 29.82
Neogen (NEOG) United States $3.465B 57.97
Hutchison China MediTech (HCM) Hong Kong, SAR China $3.150B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.132B 0.00
Quidel (QDEL) United States $2.821B 26.77
Aurora Cannabis (ACB) Canada $2.691B 0.00
National Vision Holdings (EYE) United States $2.343B 52.89
Agios Pharmaceuticals (AGIO) United States $2.303B 0.00
Cardiovascular Systems (CSII) United States $1.547B 0.00
InMode (INMD) Israel $1.406B 0.00
Aphria (APHA) $1.192B 0.00
AtriCure (ATRC) United States $1.173B 0.00
VAREX IMAGING (VREX) United States $1.126B 22.55
Phibro Animal Health (PAHC) United States $0.980B 18.35
NanoString Technologies (NSTG) United States $0.937B 0.00
Lantheus Holdings (LNTH) United States $0.791B 19.75
Eagle Pharmaceuticals (EGRX) United States $0.778B 29.79
TG Therapeutics (TGTX) United States $0.778B 0.00
LeMaitre Vascular (LMAT) United States $0.719B 40.43
Quanterix (QTRX) United States $0.707B 0.00
PetIQ (PETQ) United States $0.645B 15.73
Cerus (CERS) United States $0.589B 0.00
Surmodics (SRDX) United States $0.561B 58.56
HEXO (HEXO) $0.555B 0.00
OraSure Technologies (OSUR) United States $0.478B 28.67
MacroGenics (MGNX) United States $0.455B 0.00
Organigram Holdings (OGI) Canada $0.442B 0.00
Owens & Minor (OMI) United States $0.416B 15.40
Utah Medical Products (UTMD) United States $0.392B 28.37
Meridian Bioscience (VIVO) United States $0.391B 13.44
Zynex (ZYXI) United States $0.351B 39.67
BioLife Solutions (BLFS) United States $0.329B 134.08
Neptune Wellness Solutions (NEPT) Canada $0.257B 0.00
United Health Products (UEEC) United States $0.256B 0.00
Bovie Medical (APYX) United States $0.250B 0.00
Viemed Healthcare (VMD) United States $0.230B 24.28
Vapotherm (VAPO) United States $0.225B 0.00
Repro-Med Systems (KRMD) United States $0.192B 0.00
Liberty Health Sciences (LHSIF) Canada $0.171B 0.00
Chimerix (CMRX) United States $0.167B 0.00
InfuSystems Holdings (INFU) United States $0.162B 814.00
Female Health (VERU) United States $0.142B 0.00
Rockwell Medical (RMTI) United States $0.138B 0.00
MTech Acquisition (KERN) United States $0.137B 0.00
Fonar (FONR) United States $0.127B 8.93
Cytosorbents (CTSO) United States $0.126B 0.00
United-Guardian (UG) United States $0.091B 23.08
Oramed Pharmaceuticals (ORMP) United States $0.088B 0.00
Chembio Diagnostics (CEMI) United States $0.071B 0.00
Nephros (NEPH) United States $0.065B 0.00
MRI Interventions (MRIC) United States $0.059B 0.00
Surface Oncology (SURF) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.037B 0.00
Trinity Biotech (TRIB) Ireland $0.025B 0.00
Senestech (SNES) United States $0.017B 0.00
GUARDION HEALTH (GHSI) United States $0.015B 0.00
Valeritas Holdings (VLRX) United States $0.013B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.012B 0.00
Myomo (MYO) United States $0.008B 0.00
Capricor Therapeutics (CAPR) United States $0.007B 0.00
NeuroMetrix (NURO) United States $0.004B 0.00
Akers Biosciences Inc (AKER) United States $0.003B 0.00